Listed by the USPTO as PERSONS, JENNA L
Tech Center 4100 • Art Units: 1600 1635 1636 1637 1653 1656 1682 4100
This examiner grants 49% of resolved cases
PERSONS, JENNA L is a USPTO patent examiner in Tech Center 4100 and Art Unit 1600. The profile covers 65 resolved cases, with a 49.2% allowance rate and a median of 1330 days to allowance. The interview lift is 63.0%, higher than the relevant non-interview comparison.
EBERHARD KARLS UNIVERSITÄT TÜBINGEN, Howard Hughes Medical Institute, and Massachusetts Institute of Technology are the top companies shown. The top firms are BANNER & WITCOFF, LTD., FISH & RICHARDSON P.C. (TC), and Baker, Donelson, Bearman, Caldwell & Berkowitz, PC. The strong interview lift supports detailed interview preparation, but the smaller record and long median timing counsel against relying on the lift alone.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18535052 | Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 16772222 | CAS12B SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED DNA BASE EDITING | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17786865 | CATALYTIC NUCLEIC ACID-BASED GENETIC ENGINEERING METHOD | Final Rejection | The Board of Trustees of the University of Illinois |
| 18035901 | METHODS AND MATERIALS FOR TREATING HEART FAILURE | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18550070 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF BONE MARROW FAILURE DISEASES ASSOCIATED WITH RIBOSOMOPATHIES | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17675731 | INDUCTION OF REGULATORY B CELLS FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 17786147 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18577107 | OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS | Non-Final OA | Temple University - of the Commonwealth System of Higher Education |
| 17428322 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18730467 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | Non-Final OA | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. |
| 18246046 | FUNCTIONAL NUCLEIC ACID MOLECULES | Non-Final OA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA |
| 16395649 | HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE | Final Rejection | Sutro Biopharma, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.2% of resolved applications examined by Jenna L Persons were allowed (65 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +63.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jenna L Persons took 1,330 days on average from filing to allowance.
Jenna L Persons examines applications in Art Unit 1600 in Tech Center 4100.